Shares of Incyte Corporation (INCY) Sees Large Outflow of Money

Incyte Corporation (INCY) : The value of composite uptick trades was $13.49 million, whereas, the value of composite downtick trades was $17.53 million. The uptick to downtick ratio stood at 0.77 with a negative money flow of ($4.05) Million during Thursdays trading session. The block trades money flow was negative ($4 million). The transaction of the trades on downticks amounted to $4 million, which confirms investors selling on the strength of price. Incyte Corporation (INCY) gained 105 cents at $83.53, an increase of 1.27% over the previous days close.


Incyte Corporation (INCY) : 10 Wall Street analysts covering Incyte Corporation (INCY) believe that the average level the stock could reach for the short term is $93.6. The maximum price target given is $135 and the minimum target for short term is around $76, hence the standard deviation is calculated at $16.68. The stock has recorded a 20-day Moving Average of 5.35% and the 50-Day Moving Average is 7.1%.

Incyte Corporation (NASDAQ:INCY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $82.53 and $82.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $84.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.53, notching a gain of 1.27% for the day. The total traded volume was 699,360 . The stock had closed at $82.48 on the previous day.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *